ClinicalTrials.gg
CompletedNCT00648973Updated Aug 22, 2011

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

A Phase 4 interventional study of Diphenhydramine 50 mg and Diphenhydramine 25 mg in Nasal Congestion, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 12 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-08-22.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,021
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Nasal Obstruction with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Nasal Obstruction · United States.

Enrollment
2nd of 56
1,021 · median 51
Started
2006
with 1 other
Phase 4
4 of 65
none open now
Registered
4th of 65
by date

Among the 65 studies in Nasal Obstruction with a site in United States, this one is the 2nd largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2006, is one of 4 in phase 4, and was the 4th registered.

Nasal Obstruction

173 studies on the registry are indexed under Nasal Obstruction; 31 are open to participants now.

Browse Nasal Obstruction studies →

Open to participants now

9 of the 65 studies in Nasal Obstruction with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Nasal Obstruction studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Nasal Obstruction with a site in United States, or all of them as a file.
02

Study summary

The study was to determine if the drug worked to relieve nasal congestion experienced by people with seasonal allergies.

Read the detailed description

Subjects who met the inclusion/exclusion criteria were enrolled into the placebo run-in phase of the study on Day -7 (prerandomization, Visit 1). Baseline symptom scores were established during this run-in phase.

Subjects with moderate nasal congestion who took at least 80% of their study medication during the run-in phase were eligible for enrollment in the two-week double-blind phase of the study and were randomized on Day 1 (randomization, Visit 2). They were treated for two weeks with their assigned medication. The severity of signs/symptoms were evaluated by the subjects every morning and night and by the investigator at each visit on Day 7 and Day 14.

In addition, the subject and investigator provided a global evaluation of response to treatment on Day 7 and Day 14. Safety was evaluated by adverse events reported during the study, vital signs, and the incidence of somnolence.

03

Conditions studied

  • Nasal Congestion

Keywords

  • Seasonal Allergic Rhinitis, nasal congestion
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • otherwise healthy males and females
  • 12 to 65 years of age
  • to specific pollens for a minimum of 2 years prior to study start
  • appropriate SAR sign/symptoms scores

Exclusion criteria

Exclusion Criteria:

  • pregnancy, lactation and issues
  • medications or therapies
  • evidence of clinical, dietary, lifestyle or psychiatric issues, which in the opinion of the investigator, could increase the risk to the subject or research staff, or interfere with the interpretation of study results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,021 participants (actual)

Study arms

  • Experimental
    1

    Diphenhydramine 50 mg

    Drug: Diphenhydramine 50 mg

  • Experimental
    2

    Diphenhydramine 25 mg

    Drug: Diphenhydramine 25 mg

  • Active comparator
    3

    Pseudoephedrine 120 mg

    Drug: Pseudoephedrine 120 mg

Interventions

  • Three times daily: two diphenhydramine 25 mg capsules Twice daily: one pseudoephedrine-matching placebo tablet

    Also known as: Active: Lot # 070PB6 Formula # W015990-0002

  • Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule Twice daily: one pseudoephedrine-matching placebo tablet

    Also known as: Active: Lot # 070PB6 Formula # W015990-0002

  • Three times daily: two diphenhydramine-matching placebo capsules Twice daily: one pseudoephedrine 120 mg tablet

    Also known as: Active: Lot # INT-06-115 Formula # W015721-0004

06

What researchers measure

Primary outcomes

  1. Change from baseline in the subject's mean reflective nasal congestion/stuffiness symptom score

    Time frame: every 12-hours over the 14-day treatment period

Secondary outcomes

  1. Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score

    Time frame: 14 Days

  2. Change from baseline in the subject's mean instantaneous TNS Score

    Time frame: 14 Days

  3. Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score

    Time frame: 14 Days

  4. Change from baseline in the subject's mean instantaneous TSS Score

    Time frame: 14 Days

  5. Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness

    Time frame: 14 Days

  6. Change from baseline in the subject's mean instantaneous score for each of the eight individual SAR symptoms

    Time frame: 14 Days

  7. Onset of action for diphenhydramine treatment for nasal congestion/stuffiness was determined by comparing the change from baseline in the subject's instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo

    Time frame: taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose.

  8. Onset of action for diphenhydramine treatment for allergic rhinitis symptoms was determined by comparing the change from baseline in the subject's instantaneous TNS scores for diphenhydramine versus placebo

    Time frame: taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose

  9. Duration of action for diphenhydramine for treatment of nasal congestion/stuffiness was evaluated by comparing the change from baseline in the subject's mean instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo

    Time frame: taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)

  10. Duration of action for diphenhydramine for treatment of allergic rhinitis symptoms was evaluated by comparing the change from baseline in the subject's mean instantaneous TNS scores for diphenhydramine versus placebo

    Time frame: taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)

  11. Time to maximal effect was assessed by a by-day analysis of the primary efficacy endpoint and select secondary endpoints

    Time frame: 14 Days

  12. Subject's global evaluation of response to treatment

    Time frame: at Visits 3 and 4, analyzed separately at each visit

  13. Change from baseline in the Investigator's TNS score

    Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1

  14. Change from baseline in the Investigator's TSS score

    Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1

  15. Change from baseline for each of the eight individual Investigator's SAR symptoms

    Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1

  16. Investigator's global evaluation of the subject's response to treatment

    Time frame: at Visits 3 and 4, analyzed separately for each visit

  17. Number and percentage of subjects experiencing adverse events

    Time frame: Duration of study

  18. Change from baseline and potentially clinically important vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate)

    Time frame: Duration of study

  19. Occurrence of somnolence

    Time frame: Overall and weekly

07

Study locations

12 sites
  • Benchmark Research - Austin
    Austin, Texas 78705, United States
  • Allergy and Asthma Associates
    Austin, Texas 78731, United States
  • Lovelace Scientific Resources
    Austin, Texas 78759, United States
  • Allergy/Immunology Research Center of North Texas
    Dallas, Texas 75230, United States
  • Kerrville Research Associates
    Kerrville, Texas 78028, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Benchmark Research - San Angelo
    San Angelo, Texas 76904, United States
  • Sun Research Institute
    San Antonio, Texas 78205, United States
  • Biogenics Research Institute
    San Antonio, Texas 78229, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Apr 1, 2008
Start
Nov 2006
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Aug 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00648973
Responsible party
Sponsor
First posted
Apr 1, 2008
Start date
Nov 2006
Primary completion
May 2007
Completion
May 2007
Last update
Aug 22, 2011

Study contacts

Melissa Israel, BS
study director · McNeil Consumer Healthcare Division of Mc-Neil-PPC, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphenhydramine

Start the discussion